Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $13.8 million.

  • Xeris Biopharma Holdings' Treasury Shares changed N/A to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year change of. This contributed to the annual value of $16.4 million for FY2024, which is 4180.73% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Treasury Shares stood at $13.8 million.
  • In the past 5 years, Xeris Biopharma Holdings' Treasury Shares ranged from a high of $16.4 million in Q4 2024 and a low of $2.1 million during Q3 2021
  • For the 5-year period, Xeris Biopharma Holdings' Treasury Shares averaged around $11.2 million, with its median value being $13.8 million (2025).
  • Its Treasury Shares has fluctuated over the past 5 years, first soared by 12032.95% in 2023, then soared by 4180.73% in 2024.
  • Xeris Biopharma Holdings' Treasury Shares (Quarter) stood at $2.1 million in 2021, then soared by 154.76% to $5.3 million in 2022, then surged by 120.33% to $11.6 million in 2023, then surged by 41.81% to $16.4 million in 2024, then fell by 16.1% to $13.8 million in 2025.
  • Its Treasury Shares was $13.8 million in Q3 2025, compared to $14.5 million in Q2 2025 and $15.1 million in Q1 2025.